Gimlet Labs, Inc. | $80,000,000 | (Mar 26, 2026)
Highlight(US) | $40,000,000 | (Mar 26, 2026)
BrainGrid | $1,000,000 | (Mar 26, 2026)
A-Alpha Bio
United States
- Seattle, Washington
- 26/07/2023
- Series A
- $22,400,000
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications.
A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
- Industry Biotechnology Research
- Website https://www.aalphabio.com/
- LinkedIn https://www.linkedin.com/company/aalphabio/
Related People
David YoungerCo Founder
United States -
Seattle, Washington
A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.
NOPALERA | $4,000,000 | (Mar 26, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Worth AI | $30,000,000 | (Mar 26, 2026)
Moda | $7,500,000 | (Mar 26, 2026)
Miraterra Technologies Corporation | $11,566,320 | (Mar 26, 2026)
Hanover Park | $27,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)
Talino Fintech Foundry | $7,500,000 | (Mar 26, 2026)
Doctronic | $40,000,000 | (Mar 26, 2026)